GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Scinai Immunotherapeutics
Scinai is an Israeli biotech company with a complex history. Its stock price reflects its struggle to find its niche, including contract manufacturing of vaccines and developing its own drugs, making its path uncertain.
Share prices of companies in the market segment - Pharma immune
Scinai Immunotherapeutics is an Israeli biotech company developing innovative vaccines and immunotherapeutics. We've categorized it as a Pharmaceutical: Immunology company. The chart below shows how investors value companies at the forefront of vaccine development.
Broad Market Index - GURU.Markets
Scinai Immunotherapeutics is an Israeli biopharmaceutical company developing innovative drugs for the treatment of inflammatory and immune diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
SCNI - Daily change in the company's share price Scinai Immunotherapeutics
For Scinai Immunotherapeutics Ltd., a biopharmaceutical company, daily price change is a measure of high volatility. It reflects the market's reaction to drug development news and is critical to risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
Scinai Immunotherapeutics is a biopharmaceutical company developing vaccines and treatments for immune diseases. The vaccine sector is highly volatile and news-driven. The chart below reflects the average fluctuations in this industry, providing context for evaluating SCNI stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Scinai Immunotherapeutics is an Israeli biotech company developing vaccines and immunotherapeutic drugs. Its shares are driven by news of clinical trials, adding an element of high scientific volatility to the overall market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Scinai Immunotherapeutics
Scinai Immunotherapeutics' year-over-year performance is a story of its transformation into a contract manufacturing organization (CDMO). Its 12-month market cap reflects its success in attracting customers to its manufacturing facilities following the failure of its own COVID-19 vaccine. Its valuation is a bet on its new business model.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech, Scinai is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Scinai Immunotherapeutics is a biotech company whose stock performance is entirely dependent on the results of vaccine clinical trials. A comparison with the market clearly demonstrates that its investors are focusing not on macroeconomics but on lab news. Its path is a series of binary events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Scinai Immunotherapeutics
Scinai is an Israeli biopharmaceutical company. Its monthly performance depends on progress in its clinical programs and its ability to secure manufacturing contracts with other companies. Partnership news is a key driver.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Scinai Immunotherapeutics is a biotechnology company developing innovative immunotherapeutic drugs. The chart below reflects the overall sentiment in the immunological pharmaceutical sector, one of the fastest-growing and most promising in science.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Scinai Immunotherapeutics is an Israeli biotech company. Its shares are driven by clinical trial results and partnership news. The company's performance is largely uncorrelated with the broader market, betting on scientific advances in vaccine and antibody development.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Scinai Immunotherapeutics
Shares of Scinai Immunotherapeutics, an Israeli biopharmaceutical company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials of their innovative vaccines and therapeutics. The chart below illustrates how short-term scientific events can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Scinai Immunotherapeutics develops innovative vaccines and immunotherapy drugs. Like many biotech companies, its shares move not with the market, but with news about clinical trials. The chart will show how much its fate depends on success in the lab, rather than on general trends in the pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Scinai Immunotherapeutics is a biotech company. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Share price movements are driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
SCNI - Market capitalization of the company Scinai Immunotherapeutics
Scinai Immunotherapeutics's market capitalization reflects its transformation and search for a new niche following the COVID-19 vaccine failure. This Israeli biotech company's market capitalization now depends on the success of its new projects, including the development of biologics. Its dynamics highlight this risky restructuring.
SCNI - Share of the company's market capitalization Scinai Immunotherapeutics within the market segment - Pharma immune
Scinai Immunotherapeutics' market share in the pharmaceutical industry reflects its focus on developing innovative vaccines and immunotherapeutics. Its market share reflects the value of its scientific platform, particularly its nanobody technology, which could lead to the creation of a new generation of biotherapeutics.
Market capitalization of the market segment - Pharma immune
Here's a chart of the total market capitalization of biotech companies developing vaccines and immunotherapies. Scinai Immunotherapeutics is one such player. The chart shows how the market views this high-risk field, where clinical trial success could lead to explosive growth.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of an Israeli vaccine developer. Scinai Immunotherapeutics's market cap reflects its efforts to develop innovative drugs. The line shows how a small biotech company is fighting for its share in the highly competitive global healthcare industry.
Book value capitalization of the company, segment and market as a whole
SCNI - Book value capitalization of the company Scinai Immunotherapeutics
Scinai Immunotherapeutics' book value represents its research and production capital. The chart below reflects the valuation of its vaccine platform patents and its manufacturing capacity. Growth in the pipeline reflects investment in the development and production of innovative biologics.
SCNI - Share of the company's book capitalization Scinai Immunotherapeutics within the market segment - Pharma immune
Scinai Immunotherapeutics' tangible assets include its manufacturing facilities and laboratories for the development and production of vaccines and biological drugs. The chart shows the company's share of this pharmaceutical infrastructure, which forms the physical basis for its innovative products.
Market segment balance sheet capitalization - Pharma immune
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Scinai, as a development company, has a more streamlined model. Its value lies in its unique scientific platform, not in the scale of its production.
Book value of all companies included in the broad market index - GURU.Markets
Scinai Immunotherapeutics develops innovative vaccines and immunotherapeutic drugs. The company's assets are not massive factories, but rather a cutting-edge scientific platform and production facilities for biological drugs. The chart below shows the financial weight behind this immune system "factory."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biopharmaceutical company developing vaccines and treatments for immune diseases. Its market value is determined by the valuation of its scientific platform and its pipeline of drug candidates.
Market to book capitalization ratio in a market segment - Pharma immune
Scinai Immunotherapeutics Ltd. is an Israeli biotechnology company developing vaccines and immunotherapy drugs. Its value depends on the success of its scientific developments. This chart shows how the market valuation is a bet on the future and is significantly disconnected from its current tangible assets.
Market to book capitalization ratio for the market as a whole
Scinai Immunotherapeutics is a biopharmaceutical company developing innovative immunotherapeutic drugs, including vaccines. This chart shows how the market values their scientific platform and development pipeline. This valuation is almost entirely dependent on clinical trial success and partnerships.
Debts of the company, segment and market as a whole
SCNI - Company debts Scinai Immunotherapeutics
Scinai Immunotherapeutics, a biotech company, is leveraging its financial structure to develop its vaccine platform. This chart shows how the company is raising capital to fund preclinical and early clinical trials, a high-risk but potentially important area of healthcare.
Market segment debts - Pharma immune
Scinai Immunotherapeutics is an Israeli biotechnology company developing vaccines and immunotherapeutics. This chart shows how its debt policy reflects the high risk and capital intensity of its research, as well as the need for funding to conduct clinical trials and bring its innovative biological products to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Scinai Immunotherapeutics
Lion Group Holding is a financial company offering trading and asset management services, often focusing on Asian markets. This chart shows its capital structure. In the financial sector, leverage can be used to increase trading volume, increasing both potential profit and risk.
Market segment debt to market segment book capitalization - Pharma immune
Scinai Immunotherapeutics is an Israeli biotech company developing innovative vaccines and immunotherapeutic drugs. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its clinical-stage research platforms.
Debt to book value of all companies in the market
Scinai Immunotherapeutics is a biopharmaceutical company developing vaccines and antibody-based therapies. Biotechnology requires significant and risky investments. This chart of total market debt provides insight into the overall availability of capital, a key factor in funding the long-term clinical programs of such innovative companies.
P/E of the company, segment and market as a whole
P/E - Scinai Immunotherapeutics
For Scinai Immunotherapeutics, a biopharmaceutical company, the P/E ratio is irrelevant. The company has no consistent sales revenue. Any values on this chart are random. Investors evaluate the company solely on the potential of its pipeline and the likelihood of success in clinical trials.
P/E of the market segment - Pharma immune
Scinai Immunotherapeutics is an Israeli biopharmaceutical company developing innovative biologics. Its flagship development is a recombinant albumin protein, which can be used for various therapeutic purposes. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value companies with unique technology platforms.
P/E of the market as a whole
Scinai Immunotherapeutics (formerly BiondVax) is an Israeli biopharmaceutical company developing innovative biologics, including a universal flu vaccine and nanoantibodies. This risk appetite chart helps understand how investors value biotech companies working on complex scientific challenges.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Scinai Immunotherapeutics
Scinai Immunotherapeutics is an Israeli biopharmaceutical company developing innovative vaccines and immunotherapeutics. This chart reflects market expectations for the success of its scientific platform. Future revenue depends on clinical trial results and partnerships with major pharmaceutical companies.
%20P%2FE%20Scinai%20Immunotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Scinai-Immunotherapeutics&v=1772656379622 "Chart of the company's future (projected) P/E Scinai Immunotherapeutics")
Future (projected) P/E of the market segment - Pharma immune
Scinai Immunotherapeutics is a biotech company developing innovative vaccines and immunotherapeutic drugs. This chart reflects market expectations and hopes. It shows how investors view the company's scientific platform and its chances of success in clinical trials compared to other immunology startups.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772656379642 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Scinai Immunotherapeutics is a biopharmaceutical company developing innovative biological drugs and vaccines. Its business model includes both in-house development and contract manufacturing. Success depends on scientific breakthroughs and investment in the sector. This chart, demonstrating market optimism, reflects investor willingness to fund cutting-edge biopharmaceuticals.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772656379654 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biopharmaceutical company developing innovative biological drugs. Being in the R&D stage, its financial activities are focused on research. This chart illustrates the financial path of a biotech company, where current expenses are an investment in a scientific platform that can generate significant future revenue.
Profit of companies in the market segment - Pharma immune
Scinai Immunotherapeutics is a biotech company developing innovative anti-inflammatory and immunomodulatory drugs. This graph, showing overall sector profitability, reflects the potential of new treatment approaches. Scinai's success in developing effective and safe drugs could open new markets and have a significant impact on the entire industry.
Overall market profit
Scinai Immunotherapeutics is an Israeli biotechnology company developing innovative vaccines and immunotherapeutics. Its scientific platform is aimed at creating more effective and safe biological drugs. Like other R&D companies, its value lies in its future potential, not its current revenue.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Scinai Immunotherapeutics
Scinai Immunotherapeutics is an Israeli biopharmaceutical company developing innovative biologics. The future revenue projections presented here are speculative and depend on the success of its developments, including the Vaxil project and nanoantibodies. These expectations are based on the potential of its scientific platform.
%20profit%20of%20the%20company%20Scinai%20Immunotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Scinai-Immunotherapeutics&v=1772656379767 "Graph of future (projected) profit of the company Scinai Immunotherapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Scinai Immunotherapeutics develops innovative biologics, including anti-inflammatory agents and vaccines. This chart shows revenue forecasts for the entire immunological pharmaceuticals segment. It allows one to assess how the company's scientific platform and product portfolio compare to overall biologics market expectations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772656379773 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Scinai Immunotherapeutics is a biotech company developing innovative vaccines and therapeutics. Its future depends on scientific breakthroughs. This chart, reflecting the investment climate, is of great importance to Scinai. During periods of market optimism, investors are more willing to fund promising but risky healthcare projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772656379796 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biotech company developing innovative biologics and vaccines. This chart, plotting market capitalization against minimal or no revenue, reflects pure potential. It shows how highly investors value its scientific platform and development pipeline, anticipating future success.
P/S market segment - Pharma immune
Scinai Immunotherapeutics is a biopharmaceutical company specializing in the development, production, and commercialization of biological therapies, including vaccines and therapeutic proteins. This chart shows investor estimates of revenue in the immunotherapy sector, demonstrating expectations for Scinai's manufacturing capacity and development pipeline.
P/S of the market as a whole
Scinai Immunotherapeutics is an Israeli biopharmaceutical company developing innovative anti-inflammatory and immunotherapeutic drugs. This chart, showing average revenue estimates, demonstrates that the valuation of such companies is based on the future potential of their research and development, not on current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biotechnology company developing innovative vaccines and immunotherapeutics. This chart shows the market's assessment of its potential future revenue. It reflects investor confidence in its scientific platform and the commercial potential of its clinical trials.
%20P%2FS%20Scinai%20Immunotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Scinai-Immunotherapeutics&v=1772656379847 "The graph of the company's future (projected) P/S Scinai Immunotherapeutics")
Future (projected) P/S of the market segment - Pharma immune
Scinai Immunotherapeutics (formerly BiondVax) is an Israeli company developing innovative biologics, including nanovaccines. The chart shows the average estimated future sales in the immunology sector. It helps understand how investors view the company's new strategy and the potential of its technology platform following the failure of the universal flu vaccine.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772656379854 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Scinai Immunotherapeutics (SCNI) is an Israeli biotech company developing vaccines and immunotherapy drugs. Their future depends on scientific breakthroughs and successful clinical trials. This graph of general economic expectations has nothing to do with their mission to create new treatments for diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772656379860 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biotech company developing innovative vaccines and therapeutics. Being in the research stage, it has no stable sales revenue. Its financial history is an investment in the future, and the graph reflects potential revenue from licensing its technologies or successful commercialization of its products.
Sales of companies in the market segment - Pharma immune
Scinai Immunotherapeutics (formerly BiondVax) is a biopharmaceutical company focused on developing vaccines and immunotherapeutics. Following a strategic reorientation, its future revenue will depend on the success of its new nanoantibody developments, a typical move for a research-stage biotech company.
Overall market sales
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing vaccines and immunotherapeutic drugs. Its success depends on scientific breakthroughs and clinical trial results. The overall economic situation, shown in this chart, influences the amount of public and private funding allocated to innovative healthcare research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biopharmaceutical company developing innovative biologic therapeutics. Its future revenue depends on the success of clinical trials and product launches. This chart represents analysts' long-term forecast of the commercial potential of its scientific platform.
%20sales%20of%20the%20company%20Scinai%20Immunotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Scinai-Immunotherapeutics&v=1772656379898 "Schedule of future (projected) sales of the company Scinai Immunotherapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Scinai Immunotherapeutics is a biopharmaceutical company developing innovative biologics, including anti-inflammatory nanobodies. This chart shows the outlook for the immunology pharmaceutical segment. It reflects the high demand for new treatments for autoimmune diseases, a key area of development for Scinai.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772656379910 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
This chart reflects the investment climate in biotech, which is critical for Scinai Immunotherapeutics. The company develops innovative vaccines and immunotherapeutic drugs. Funding for its research depends on capital inflows, which increase with positive economic forecasts.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772656379924 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biotechnology company developing innovative biological drugs and vaccines. This chart reflects its current status as a research and development organization. Future profitability depends entirely on the success of its developments in clinical trials and potential partnerships with major pharmaceutical companies.
Market segment marginality - Pharma immune
Scinai Immunotherapeutics is an Israeli biopharmaceutical company developing innovative vaccines and immunotherapeutics. Profitability depends on the success of its research and development in clinical trials. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the potential and risks associated with Scinai's technology platform.
Market marginality as a whole
Scinai Immunotherapeutics is a biopharmaceutical company developing innovative biological drugs. Its business model includes both in-house development and contract manufacturing. This graph, reflecting the state of the economy, influences the investment climate in biotech and the willingness of other companies to place orders for contract manufacturing, generating revenue for Scinai.
Employees in the company, segment and market as a whole
Number of employees in the company Scinai Immunotherapeutics
Scinai Immunotherapeutics is a biopharmaceutical company developing biologics. This chart shows the size of its scientific and manufacturing teams. The dynamics reflect the company's development stages, including periods of active research and the provision of contract manufacturing services (CDMO), which requires flexible management of its scientific and technical staff.
Share of the company's employees Scinai Immunotherapeutics within the market segment - Pharma immune
Scinai Immunotherapeutics develops innovative biologics using its vaccine and therapeutic antibody platforms. This chart shows the company's share of the total number of scientists in the fields of immunology and biologics development. This reflects its scientific potential and the breadth of its research activities.
Number of employees in the market segment - Pharma immune
Scinai Immunotherapeutics is a biopharmaceutical company developing and manufacturing innovative biologics, including vaccines. This chart, which reflects employment in the immunopharmaceutical sector, is important. The growing number of scientists and manufacturing specialists in this field indicates a high demand for new vaccines and biologics to combat various diseases.
Number of employees in the market as a whole
Scinai Immunotherapeutics is a biotechnology company developing vaccines and immunotherapeutic drugs. The development of such projects requires sustainable funding. This total employment chart reflects the economic stability necessary to attract investment in the healthcare sector and conduct long-term clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Scinai Immunotherapeutics (SCNI)
Scinai Immunotherapeutics is a biotech company (formerly BiondVax) focused on vaccine and immunotherapy development. This chart is a classic example of an R&D business. The company's value is unrelated to its headcount; it is determined entirely by the value of its scientific platform (in this case, nanobodies) and patents.
%20of%20the%20company%20Scinai%20Immunotherapeutics%20(SCNI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Scinai-Immunotherapeutics-SCNI&v=1772656380046 "Chart of market capitalization per employee (in thousands of dollars) of the company Scinai Immunotherapeutics (SCNI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Scinai Immunotherapeutics is a biotech company developing vaccines and immunotherapeutic drugs. Its value is determined by its scientific potential and development pipeline. This chart illustrates the enormous value the market can place on the intellectual work of a small team of scientists, especially compared to traditional manufacturing companies.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772656380063 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Scinai Immunotherapeutics is a biopharmaceutical company developing vaccines and immunotherapeutics. Its market capitalization is based on the potential of its scientific platform. This metric reflects a high cost per employee, which is typical in biotech, where a small team of scientists can create a product with global market potential.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772656380073 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Scinai Immunotherapeutics (SCNI)
Scinai Immunotherapeutics is an Israeli biotech company (formerly BiondVax) that, after the failure of a universal flu vaccine, focused on developing other biologics. This chart shows the "reboot cost": how much the company spends (negative profit) on each scientist trying to find a new, successful R&D program.
%20Chart%20Scinai%20Immunotherapeutics%20(SCNI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Scinai-Immunotherapeutics-SCNI&v=1772656380083 "Company Profit Per Employee (in thousands of dollars) Chart Scinai Immunotherapeutics (SCNI)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Scinai Immunotherapeutics is a biotechnology company developing vaccines and immunotherapeutic drugs. For a company in clinical trials, this chart reflects capital management efficiency. Positive dynamics in this indicator will be possible after successful completion of trials and the launch of products on the market, or the conclusion of licensing agreements.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772656380099 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Scinai Immunotherapeutics (SCNI) is an Israeli biopharmaceutical company (formerly BiondVax) developing new vaccines and therapeutics. It is an R&D company and has no profit. This indicator is negative and reflects the investment in research personnel who create intellectual property (new vaccine platforms).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772656380119 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Scinai Immunotherapeutics (SCNI)
Scinai Immunotherapeutics is a biopharmaceutical company developing vaccines and immunotherapy drugs. While in the development stage, it may not generate significant revenue. This graph is important for assessing the potential of its scientific platform and future products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Scinai-Immunotherapeutics-SCNI&v=1772656380152 "Sales chart per company employee Scinai Immunotherapeutics (SCNI)")
Sales per employee in the market segment - Pharma immune
Scinai Immunotherapeutics is an Israeli biotech company developing a nanoantibody (VHH) platform for the treatment of inflammatory and autoimmune diseases. This is an R&D company. This graph reflects their clinical stage. The productivity of their research team lies in the creation and advancement of drug candidates, not in ongoing sales.
Sales per employee for the market as a whole
The Andersons (ANDE) is a diversified company operating in the agricultural sector. Their businesses include grain trading, logistics, ethanol, and fertilizer production. This is the "real" sector, connecting farmers to the market. This chart reflects efficiency in the commodity business. Success here depends on managing logistics (elevators, rail) and trading margins. Automation allows the company to move huge volumes of produce.
Short shares by company, segment and market as a whole
Shares shorted by company Scinai Immunotherapeutics (SCNI)
Scinai (SCNI) is an Israeli biopharmaceutical company developing vaccines and biologics. This chart tracks short positions. The shorts may be related to the company's (formerly BiondVax) long history of failures and skepticism about its new projects.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Scinai-Immunotherapeutics-SCNI&v=1772656380294 "Short Shares Chart for the Company Scinai Immunotherapeutics (SCNI)")
Shares shorted by market segment - Pharma immune
Scinai Immunotherapeutics (SCNI) is a biotech company (formerly BiondVax) developing new vaccines and therapeutics. The chart below represents a general short position in the biotech sector, demonstrating investor skepticism about the success of risky clinical trials.
Shares shorted by the overall market
Scinai Immunotherapeutics is an Israeli biotech (formerly BiondVax) trying to develop new vaccines and treatments. This chart measures overall fear. When investors are afraid, they avoid stocks with dual risks: scientific (trial failure) and geopolitical (Israel). SCNI, with its history of R&D failures, becomes an easy target for sell-offs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Scinai Immunotherapeutics (SCNI)
This chart for Scinai is a barometer of "second chances" in biotech. The company (formerly BiondVax) failed flu vaccine trials and is now trying to become a contract manufacturer (CDMO) and is also developing nanovaccines. "Overheating" (above 70) occurs on contract announcements. Lack of revenue and the failure of a previous project lead to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Scinai-Immunotherapeutics-SCNI&v=1772656380648 "RSI 14 indicator chart for the company's stock Scinai Immunotherapeutics (SCNI)")
RSI 14 Market Segment - Pharma immune
Scinai Immunotherapeutics (formerly BiondVax) is an Israeli biopharmaceutical company (CDMO) that provides biologic drug development and manufacturing services to other companies. This chart reflects the overall sentiment in the biotech sector, helping to gauge the overall market sentiment toward this speculative industry.
RSI 14 for the overall market
Scinai Immunotherapeutics (SCNI) is a biotech company developing vaccines and immunotherapy drugs. Its value depends on the success of its R&D. This market "temperature" chart shows investors' overall risk appetite. When the market is "overheated" (euphoric), investors are willing to fund bold scientific projects. In moments of panic (oversold), funding for companies like SCNI becomes scarce.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SCNI (Scinai Immunotherapeutics)
Scinai (SCNI) is an Israeli biotech company developing innovative immunotherapeutics, including nanobodies (NanoAbs). This chart shows the average target price. It reflects analysts' speculative assessment of this scientific platform and its chances of success in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SCNI-Scinai-Immunotherapeutics&v=1772656380684 "A chart showing analyst consensus forecasts for the expected stock price. SCNI (Scinai Immunotherapeutics)")
The difference between the consensus estimate and the actual stock price SCNI (Scinai Immunotherapeutics)
Scinai (SCNI) is an Israeli biotech company that has transformed itself into a contract manufacturing organization (CDMO) for biologics, leveraging its R&D capabilities. This chart shows how the current share price differs from its "fair" value. It reflects analysts' views on their new outsourcing business model.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SCNI-Scinai-Immunotherapeutics&v=1772656380693 "A chart showing the difference between the consensus forecast and the actual stock price. SCNI (Scinai Immunotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Scinai Immunotherapeutics is an Israeli biotech company developing "universal" vaccines (including the VaxiPatch nanovaccines) against influenza and COVID-19. This chart shows general expectations for the immune pharma sector. It reflects whether experts believe a breakthrough in "universal" vaccines is possible.
Analysts' consensus forecast for the overall market share price
Scinai Immunotherapeutics (SCNI) is an Israeli biopharmaceutical company. They are developing a platform for "Vax-in-a-Box"—a rapid vaccine development platform—and also act as a contract manufacturer (CDMO). This chart shows the overall risk appetite, reflecting the willingness of investors to invest in speculative R&D platforms after the pandemic boom.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Scinai Immunotherapeutics
Scinai Immunotherapeutics (formerly BiondVax) is a biotech company that has rebooted itself. After the failure of their universal flu vaccine, they are now using their assets (R&D, manufacturing plant) to develop new drugs (including nano-antibodies). This chart is a summary indicator of their second chance. It reflects their (speculative) new R&D pipeline and their struggle for survival.
AKIMA Market Segment Index - Pharma immune
Scinai Immunotherapeutics is an Israeli biopharmaceutical company. They use their expertise to develop new vaccines and immunotherapeutic drugs to combat infections and cancer. This chart compares their composite index to their sector, showing how their approach to immunology compares to their peers.
The AKIM Index for the overall market
Scinai Immunotherapeutics is an Israeli biotech company developing biologics (nanobodies) for the treatment of inflammation and immune diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which also offers CDMO services, compares to overall economic trends.
